INTIMATION FOR BODHIKA SEMINAR 25/10/2023
DEPARTMENT OF PRASUTI TANTRA & STREEROGA
RASASHASTRA & BHAISHAJYA KALPANA
NAME OF FIRST PRESENTEE:DR. SRUTHI L R
DISSERTATION TITLE: COMBINED EFFECT OF RAJAPRAVARTINI VATI AND CHIRUVILWADI KASHAYA IN OLIGOMENORRHOEA ASSOCIATED WITH POLYCYSTIC OVARIAN SYNDROME
TIME: 2:00-4:00 PM
VENUE: COLLEGE AUDITORIUM
ABSTRACT
Polycystic Ovarian Syndrome is one of the most common metabolic &reproductive disorder among women of reproductive age. Changes in the lifestyle, diet, stress of modern society leads to increase in prevalence of PCOS upto 20-30%. PCOS effects the richness of feminity as infertility stands out as one of its major complications. Oligomenorrhoea is one among the most common presenting complaints in participants diagnosed with PCOS. Although no direct correlation of PCOS is found in ayurvedic classical texts. Etiopathogenesis of nastharthava, arhavakshaya, and vandhya yoni vyapath mentioned in susrutha samhitha can be considered here. Pushpagni jataharini mentioned in Kasyapa samhitha bears some similarity with this disease. Here the combined effect of Rajapravartini vati & chiruvilwadi kashaya in Oligomenorrhoea associated with PCOS were evaluated. The study drug Rajapravartini vati is mentioned under streerogadhikara in bhaishajyaratnavali and Chiruvilwadi kashaya is mentioned under arsas prakaranam in sahasrayogam. The study design is pre and post interventional study with a sample size of 30. Females in age group of 18-40 years diagnosed as having Oligomenorrhoea associated with PCOS as per Rotterdam criteria 2003, satisfying inclusion and exclusion criteria attending the OPD of Dept of Prasutitantra and streeroga, Govt Ayurveda College, Thiruvananthapuram were selected for the study. Their symptoms were assessed before starting the treatment using a case proforma, USG and necessary lab investigations. In this study 125 mg of Rajapravartini vati followed by intake of 48 ml of Chiruvilwadi kashaya twice daily before food were adviced to the participants for 90 days. Administration of drug starts on the 1st day of visit and continued till the onset of next menstrual cycle excluding the 3 days of menstruation for three consecutive cycles. Follow up without medicines was done for next 3 consecutive cycles. Data obtained was analysed statistically. The study drug was found to be effective in normalizing menstrual interval, reducing the ovarian volume and reducing the BMI, without causing changes in duration of menstruation, amount of bleeding and haemoglobin level with in the study period.
NAME OF SECOND PRESENTEE:DR. SRUTHI KRISHNAN
DISSERTATION TITLE: COMBINED EFFECT OF PHALASARPIS AND SHATAVARI CHURNA IN MANAGEMENT OF DIMINISHING OVARIAN RESERVE AMONG INFERTILE WOMEN
TIME: 2:00-4:00 PM
VENUE: COLLEGE AUDITORIUM
ABSTRACT
Diminishing Ovarian Reserve (DOR) is a condition in which the ovary loses its normal reproductive potential, compromising fertility. It is characterized by reduction in oocyte quantity, oocyte quality and reproductive potential along with abnormal ovarian reserve tests such as low serum AMH level and Antral Follicular Count. The findings of Institute for Social and Economic change (ISEC) survey highlight that on an average nearly 4% Indian women are already in menopause between the ages of 29-34 years. DOR is an important limiting factor for the success of any treatment modality for infertility. In Ayurveda, DOR can be related with Dhatukshaya vandhya, explained in Haritha Samhitha. It is the depletion of dhatu or inadequate formation of dhatu, and utharothara dhatukshaya leads to reduction in fertility potential and ultimately Anapathyatha. In this clinical study, combined effect of Phalasarpis and Shatavari churna in Diminishing Ovarian Reserve among infertile women were evaluated. The study drug Phalasarpis is mentioned under Guhyaroga prathishedha adhyaya of Ashtanga Hrudaya Uttarasthana and Shatavari is mentioned under Shatavari Shatapushpa kalpadhyaya of Kashyapa Samhitha. The study design was pre & post interventional study with a sample size of 20. Infertile women in the age group 20-40 years diagnosed with Diminishing Ovarian Reserve (DOR) attended the OPD of Department of Prasutitantra & Streeroga, Government Ayurveda College, Thiruvananthapuram were selected for the study as per inclusion and exclusion criteria. The selected participants were given 12ml of Phalasarpis with 6gm of Shatavari churna twice a day before food with hot water as anupana for a period of 90 days. Data collection was done by case proforma, lab investigations and markers of ovarian reserve such as serum AMH level and Antral Follicular Count (AFC) by transvaginal ultrasonography. Assessment of serum AMH level and AFC were done on the 2nd/3rd day of first menstrual cycle (before treatment) and 2nd/3rd day of menstrual cycle after completing administration of medicines. Results were analysed using Wilcoxon signed rank test, Chi-squared test and Fishers exact test. Statistical analysis of data showed that the study had significant effect on Antral Follicular Count(P<0.001), amount of menstrual bleeding(P=0.021), vaginal dryness(P=0.003) and dyspareunia(P=0.003). P value 0.083 suggests the treatment may have led to slight increase in S.AMH level although the difference is not statistically significant. Three out of 20 participants conceived during the treatment period, indicating a 15% success rate. Thus, the study concludes that oral administration of combination of Phalasarpis and Shatavari churna had a significant effect in management of Diminishing Ovarian Reserve among infertile women.
NAME OF FIRST PRESENTEE:DR.SANDRA T SAJI
DISSERTATION TITLE: ANTHELMINTIC ACTIVITY OF PIPPALYADI CHURNA AND ITS INGREDIENTS AS STAND-ALONE AND IN COMBINATION WITH ALBENDAZOLE IN Pheretima posthuma AND Ascaridia galli
TIME: 2:00-4:00 PM
VENUE: COLLEGE AUDITORIUM
ABSTRACT
Helminthiasis is a significant health concern among impoverished communities, affecting about 24% of the global population. Albendazole, Thiabendazole, and Ivermectin are widely used antihelminthics, but their side effects often prompt safer and more effective treatments. Pippalyadi Churna is a polyherbal medicine detailed in Ayurvedic treatises for helminthiasis and related conditions. To understand the antihelminthic activity of the test samples, we carried out the ovicidal activity by Egg Hatch Assay, the larvicidal activity by Larval Motility Assay, and the adulticidal activity in Pheretima posthuma and Ascaridia galli using various concentrations of extracts of Pippalyadi Churna and its ingredients. Albendazole was the positive control, and respective blank solutions were negative controls. The Pippalyadi Churna and its components showed significant adulticidal activity (P<0.05, one-way ANOVA with Tukey's multiple comparisons), while Albendazole had an IC50 value of 48.72mg/ml. Pippalyadi Churna, Hingu (Ferula asafoetida), and Vidanga (Embelia ribes) induced considerable mortality in Pheretima posthuma (IC50 68.5883, 72.10665 and 67.5188 mg/ml) and Ascaridia galli (IC50 107.7246, 121.6389 and 84.1342 mg/ml). Albendazole exhibited an IC50 value of about 48 mg/ml in both organisms. Importantly, we noticed a significant reduction in Albendazole's IC50 value in adulticidal activity when coadministered with Pippalyadi Churna, Hingu, and Vidanga, possibly due to synergetic effects. The presence of polyphenolic compounds in the Churna and its ingredients and transferulic acid, a bioactive compound known for its antihelminthic activity, in Pippalyadi Churna and Hingu, might have contributed to their antihelminthic activities. The experiment signifies further studies to develop safe and effective antihelminthic drug regimens consisting of Ayurvedic medicines and antihelminthic drugs.
No comments:
Post a Comment